PharVision Advisers’s Antero Midstream AM Stock Holding History

PharVision Advisers’s Portfolio AM Stock Details AM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,192	Closed	-$269K	–	662
2025 Q2	$269K	Buy	+14,192	New	+$254K	0.39%	105

Other funds holding AM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TCA

Tortoise Capital Advisors Overland Park, Kansas $9.6B AUM 19.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's AM Position: Q3 2025 in Review

PharVision Advisers sold out of Antero Midstream (AM) in Q3 2025, closing a stake of 14,192 shares — an estimated $269K sold.

PharVision Advisers first reported a position in AM in Q2 2025 and held it in 1 quarter. The position peaked at $269K in Q2 2025. 464 funds tracked by Wall St. Rank hold AM as of Q3 2025.

PharVision Advisers reported no remaining Antero Midstream position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 14,192 Antero Midstream shares in Q3 2025, an estimated $269K.
PharVision Advisers first reported a position in Antero Midstream in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Antero Midstream position peaked at $269K in Q2 2025.
464 funds tracked by Wall St. Rank held Antero Midstream as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.